XRME:F:F-Xtrackers MSCI USA ESG Screened UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 10.264

Change

+0.10 (+1.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.84 (+1.62%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

+5.60 (+1.02%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+1.00 (+1.74%)

USD 108.41B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 52.77B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.85 (+1.22%)

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

+1.03 (+1.05%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 46.87B
0ZC:F Zscaler Inc

+2.00 (+0.88%)

USD 37.92B
BSND:F Danone SA

N/A

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

+0.88 (+0.69%)

USD 24.77B

ETFs Containing XRME:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.15% 42% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.15% 43% F 50% F
Trailing 12 Months  
Capital Gain 9.94% 79% B- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.94% 76% C+ 61% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.39% 84% B 73% C
Dividend Return 13.39% 82% B 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.55% 51% F 86% B+
Risk Adjusted Return 106.69% 95% A 95% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike